NetworkNewsBreaks – Predictive Oncology Inc.’s
Post# of 281
(Total Views: 196)
Posted On: 10/02/2020 5:56:36 PM
NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CIO Discusses Convergence of AI, Data and Biology on DojoLIVE!
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (http://nnw.fm/XeQG6). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 tumors in an effort to personalize cancer therapies and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Collins addressed this powerful work and his longtime passion during the interview titled, “Can We Cure Cancer with Artificial Intelligence?” “The last 20 years of my career, I’ve been trying to realize that vision of how the convergence of AI, data and biology can be used to discover new drugs,” he said, noting that Helomics holds a massive collection of data and AI capabilities. “And it’s that convergence of AI, the big data, if you will, and the biology, where we’re able to test drugs on living tumor tissue rather than some artificial system, that we really believe will revolutionize drug discovery and impact the patients of tomorrow.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent article discussing the appearance of one of its executives, Helomics CIO Mark Collins, PhD, on DojoLIVE! (http://nnw.fm/XeQG6). POAI’s Helomics subsidiary applies AI to its rich data gathered from more than 150,000 tumors in an effort to personalize cancer therapies and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Collins addressed this powerful work and his longtime passion during the interview titled, “Can We Cure Cancer with Artificial Intelligence?” “The last 20 years of my career, I’ve been trying to realize that vision of how the convergence of AI, data and biology can be used to discover new drugs,” he said, noting that Helomics holds a massive collection of data and AI capabilities. “And it’s that convergence of AI, the big data, if you will, and the biology, where we’re able to test drugs on living tumor tissue rather than some artificial system, that we really believe will revolutionize drug discovery and impact the patients of tomorrow.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)